StockData

Kura Oncology vs Syndax Pharmaceuticals

KURA and SNDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KURA and SNDX compare

Syndax Pharmaceuticals is the larger company, worth 1.2 times as much as Kura Oncology ($822M against $666M).

Syndax Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −72.3% compared with −369% at Kura Oncology.

Syndax Pharmaceuticals scores higher on the StockData Score (3 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKURASNDX
Size and price
Market cap$666M$822M
Share price$7.49$9.20
Change, 1 year−33.2%−44.6%
Change, 5 years−46.5%−44.2%
Beta (5Y)2.301.72
Employees260298
StockData Score
Total score13 (better)
Valuation score01 (better)
Growth score01 (better)
Performance score00
Health score11
Dividend score00
Valuation
P/S8.4×2.8× (better)
P/B37.1×–
FCF yield−13.4%–
Growth
Revenue growth (TTM)–160%
Revenue growth, 5Y average–158%
Profitability
Operating margin−394%−61.7% (better)
Net margin−369%−72.3% (better)
FCF margin−112%–
Return on equity−225% (better)−426%
Financial health
Debt / equity0.55–
Interest coverage−227.1× (better)−44660.0×
Current ratio3.604.69 (better)
Altman Z-score−3.56−2.30 (better)
Piotroski F-score13 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions98.0%121%
Held by insiders2.7%1.8%
Insider net buying, 12 months$512K (better)−$2.9M
Short interest, % of float14.6%21.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.